Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 254

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 254
---
 |
| CORPORATE SOCIAL RESPONSIBILITY               |                                                                                                                                                                                                                                                                                                                                                    |
| l                                             | Monitoring of progress on the CSR strategy.                                                                                                                                                                                                                                                                                                        |
| l                                             | Monitoring of objectives for gender representation in executive bodies, and more generally of Sanofi's diversity policy in accordance withlegislation.                                                                                                                                                                                             |
| l                                             | Monitoring of Sanofi's equal pay and equal opportunity policy.                                                                                                                                                                                                                                                                                     |
| «                                             | Ethics and corporate culture update – feedback on the "Your Voice" survey.                                                                                                                                                                                                                                                                         |
| «                                             | Implementation of the European Corporate Sustainability Reporting Directive (CSRD).                                                                                                                                                                                                                                                                |

| lAnnual items | «Non-recurring items |

| SANOFIFORM 20-F2024 | 149 |

| PART I                                             |
| ITEM 6. Directors, Senior Management and Employees |

In addit ion, two strategy seminars were held, in April and October 2024, in which all members of the Executive Committee took part. The seminar gave directors an opportunity to address issues including: • monitoring delivery of phase 2 of the the Play to Win strategy; • feedback from “Strat Days” (a two-day Executive Committee meeting designed to address long-term strategic decisions); • modernization of Manufacturing & Supply; • R&D transformation plan; • mergers & acquisitions in the pharmaceutical market over the past few years; • update on mergers & acquisitions strategy; • in-depth review of mRNA; and • emerging markets strategy, especially in China. Remit and Operation of Board Committees Our Board of Directors is assisted in its deliberations and decisions by five specialist Committees (for a description of the remit of each Committee, refer to our Board Charter, provided as Exhibit 1.2 to this annual report ). Chairs and members of these Committees are chosen by the Board from among its members, based on their experience. The Committees are responsible for the preparation of certain items on the agenda of the Board of Directors. Decisions of the Committees are adopted by a simple majority with the Chair of the Committee having a casting vote. Minutes are prepared, and approved by the Committee members. The Chair of each Committee reports to the Board on the work of that Committee, so that the Board is fully informed whenever it takes a decision. Audit Committee Composition of the Committee in 2024

| Audit Committee | Composition as of January 1, 2024                                                           | Composition as of December 31, 2024                                                                                                                      |
|:----------------|:--------------------------------------------------------------------------------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------|
| Chair           | Fab